Recro Pharma Inc (NASDAQ:REPH) major shareholder Scp Vitalife Partners (Israel) sold 12,964 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $8.88, for a total value of $115,120.32. Following the completion of the sale, the insider now owns 734,269 shares in the company, valued at approximately $6,520,308.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Scp Vitalife Partners (Israel) also recently made the following trade(s):
- On Friday, December 28th, Scp Vitalife Partners (Israel) sold 1,980 shares of Recro Pharma stock. The shares were sold at an average price of $9.44, for a total value of $18,691.20.
Shares of Recro Pharma Inc (NASDAQ REPH) opened at $8.69 on Friday. Recro Pharma Inc has a 52-week low of $5.81 and a 52-week high of $10.59. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50.
A number of equities research analysts have commented on the company. Zacks Investment Research lowered Recro Pharma from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. Piper Jaffray Companies reiterated a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a research report on Friday, October 27th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $11.65.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.